Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease : Analyses Conducted for Canada, France, Italy, and Portugal
No Thumbnail Available
Date
2016-10
Journal Title
Journal ISSN
Volume Title
Publisher
Citation
Maleki-Yazdi, M R, Molimard, M, Keininger, D L, Gruenberger, J-B, Carrasco, J, Pitotti, C, Sauvage, E, Chehab, S & Price, D B 2016, 'Cost Effectiveness of the Long-Acting β2-Adrenergic Agonist (LABA)/Long-Acting Muscarinic Antagonist Dual Bronchodilator Indacaterol/Glycopyrronium Versus the LABA/Inhaled Corticosteroid Combination Salmeterol/Fluticasone in Patients with Chronic Obstructive Pulmonary Disease : Analyses Conducted for Canada, France, Italy, and Portugal', Applied Health Economics and Health Policy, vol. 14, no. 5, pp. 579-594. https://doi.org/10.1007/s40258-016-0256-z